CYTOKINETICS INC
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c) In this Item 5(c) of this quarterly report on Form 10-Q, the terms “officers”, “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” have the meanings ascribed to them in Item 408 of Regulation S-K.
The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the second quarter of 2026:
Robert E. Landry. – Mr. Landry, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement on June 12, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Landry Plan”). The Landry Plan provides for the sale of up to 2000 shares of our common stock, subject to certain conditions. The Landry Plan will terminate on theearlier of (x)June 4, 2027 and (y) the sale of all securities that are subject to the plan.
Wendell Wierenga, Ph.D. – Mr. Wierenga, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement on June 10, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Wierenga Plan”). The Wierenga Plan provides for the sale of up to 45,714 shares of our common stock, subject to certain conditions. The Wierenga Plan will terminate on theearlier of (x)May 16, 2028 and (y) the sale of all securities that are subject to the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.